Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series.
We report efficacy and safety outcomes from a prospective case series of 31 late-stage T.b. gambiense sleeping sickness (Human African Trypanosomiasis, HAT) patients treated with a combination of nifurtimox and eflornithine (N+E) in Yumbe, northwest Uganda in 2002-2003, following on a previously rep...
Published in: | PLoS Neglected Tropical Diseases |
---|---|
Main Authors: | , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Public Library of Science (PLoS)
2007
|
Subjects: | |
Online Access: | https://doi.org/10.1371/journal.pntd.0000064 https://doaj.org/article/5b9339f7beed474481b040a779a20598 |
id |
ftdoajarticles:oai:doaj.org/article:5b9339f7beed474481b040a779a20598 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:5b9339f7beed474481b040a779a20598 2023-05-15T15:10:07+02:00 Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. Francesco Checchi Patrice Piola Harriet Ayikoru Florence Thomas Dominique Legros Gerardo Priotto 2007-11-01T00:00:00Z https://doi.org/10.1371/journal.pntd.0000064 https://doaj.org/article/5b9339f7beed474481b040a779a20598 EN eng Public Library of Science (PLoS) http://europepmc.org/articles/PMC2100371?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0000064 https://doaj.org/article/5b9339f7beed474481b040a779a20598 PLoS Neglected Tropical Diseases, Vol 1, Iss 2, p e64 (2007) Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2007 ftdoajarticles https://doi.org/10.1371/journal.pntd.0000064 2022-12-31T05:10:52Z We report efficacy and safety outcomes from a prospective case series of 31 late-stage T.b. gambiense sleeping sickness (Human African Trypanosomiasis, HAT) patients treated with a combination of nifurtimox and eflornithine (N+E) in Yumbe, northwest Uganda in 2002-2003, following on a previously reported terminated trial in nearby Omugo, in which 17 patients received the combination under the same conditions.Eligible sequential late-stage patients received 400 mg/Kg/day eflornithine (Ornidyl, Sanofi-Aventis) for seven days plus 15 mg/Kg/day (20 mg for children <15 years old) nifurtimox (Lampit, Bayer AG) for ten days. Efficacy (primary outcome) was monitored for 24 months post discharge. Clinical and laboratory adverse events (secondary outcome) were monitored during treatment. All 31 patients were discharged alive, but two died post-discharge of non-HAT and non-treatment causes, and one was lost to follow-up. Efficacy ranged from 90.3% to 100.0% according to analysis approach. Five patients experienced major adverse events during treatment, and neutropenia was common (9/31 patients).Combined with the previous group of 17 trial patients, this case series yields a group of 48 patients treated with N+E, among whom no deaths judged to be treatment- or HAT-related, no treatment terminations and no relapses have been noted, a very favourable outcome in the context of late-stage disease. N+E could be the most promising combination regimen available for sleeping sickness, and deserves further evaluation. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic PLoS Neglected Tropical Diseases 1 2 e64 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
spellingShingle |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Francesco Checchi Patrice Piola Harriet Ayikoru Florence Thomas Dominique Legros Gerardo Priotto Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. |
topic_facet |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
description |
We report efficacy and safety outcomes from a prospective case series of 31 late-stage T.b. gambiense sleeping sickness (Human African Trypanosomiasis, HAT) patients treated with a combination of nifurtimox and eflornithine (N+E) in Yumbe, northwest Uganda in 2002-2003, following on a previously reported terminated trial in nearby Omugo, in which 17 patients received the combination under the same conditions.Eligible sequential late-stage patients received 400 mg/Kg/day eflornithine (Ornidyl, Sanofi-Aventis) for seven days plus 15 mg/Kg/day (20 mg for children <15 years old) nifurtimox (Lampit, Bayer AG) for ten days. Efficacy (primary outcome) was monitored for 24 months post discharge. Clinical and laboratory adverse events (secondary outcome) were monitored during treatment. All 31 patients were discharged alive, but two died post-discharge of non-HAT and non-treatment causes, and one was lost to follow-up. Efficacy ranged from 90.3% to 100.0% according to analysis approach. Five patients experienced major adverse events during treatment, and neutropenia was common (9/31 patients).Combined with the previous group of 17 trial patients, this case series yields a group of 48 patients treated with N+E, among whom no deaths judged to be treatment- or HAT-related, no treatment terminations and no relapses have been noted, a very favourable outcome in the context of late-stage disease. N+E could be the most promising combination regimen available for sleeping sickness, and deserves further evaluation. |
format |
Article in Journal/Newspaper |
author |
Francesco Checchi Patrice Piola Harriet Ayikoru Florence Thomas Dominique Legros Gerardo Priotto |
author_facet |
Francesco Checchi Patrice Piola Harriet Ayikoru Florence Thomas Dominique Legros Gerardo Priotto |
author_sort |
Francesco Checchi |
title |
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. |
title_short |
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. |
title_full |
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. |
title_fullStr |
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. |
title_full_unstemmed |
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. |
title_sort |
nifurtimox plus eflornithine for late-stage sleeping sickness in uganda: a case series. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2007 |
url |
https://doi.org/10.1371/journal.pntd.0000064 https://doaj.org/article/5b9339f7beed474481b040a779a20598 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
PLoS Neglected Tropical Diseases, Vol 1, Iss 2, p e64 (2007) |
op_relation |
http://europepmc.org/articles/PMC2100371?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0000064 https://doaj.org/article/5b9339f7beed474481b040a779a20598 |
op_doi |
https://doi.org/10.1371/journal.pntd.0000064 |
container_title |
PLoS Neglected Tropical Diseases |
container_volume |
1 |
container_issue |
2 |
container_start_page |
e64 |
_version_ |
1766341179443511296 |